3 ms·

The therapy described in the article would not be allowed in Brazil https://www.mdpi.com/2077-0383/12/7/2672 https://www.mdpi.com/2077-0383/12/7/2672

• maronato 2y ago
  That’s not what the article says. It says patients have access to the treatment for free, but sometimes delivery can be delayed by a few months due to shortages. The study only considered people without health insurance and says people with health insurance don’t face the same supply shortages. > Most patients (n = 172, 83.9%) reported at least one failed delivery of biological medicine in the last year, with a single shortage in forty-two patients (24.4%), at least two shortages in forty-seven patients (27.3%), and three or more shortages in seventy-eight patients (45.3%). The average time to regularize the distribution was up to 1 month in 44 cases (25.6%), up to 2 months in 64 cases (37.2%), and more than 3 months in 56 patients (32.6%)
  • mgraczyk 2y ago
    Where does it say "free"?
    • mgraczyk 2y ago
      Relevant quote "In CD, the PCDT does not offer any biologic other than anti-TNF drugs. Despite being approved in Brazil, new biologics such as ustekinumab and vedolizumab are not available for these patients [28,29]."